Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background And Aims: Coronary thin-cap fibroatheromas (TCFA) are associated with adverse outcome, but identification of TCFA requires expertise and is highly time-demanding. This study evaluated the utility of artificial intelligence (AI) for TCFA identification in relation to clinical outcome.

Methods: The PECTUS-AI study is a secondary analysis from the prospective observational PECTUS-obs study, in which 438 patients with myocardial infarction underwent optical coherence tomography (OCT) of all fractional flow reserve-negative non-culprit lesions (i.e. target lesions). OCT images were analyzed for the presence of TCFA by an independent core laboratory (CL-TCFA) and OCT-AID, a recently developed and validated AI segmentation algorithm (AI-TCFA). The primary outcome was defined as the composite of death from any cause, non-fatal myocardial infarction or unplanned revascularisation at 2 years (±30 days), excluding procedural and stent-related events.

Results: Among 414 patients, AI-TCFA and CL-TCFA were identified in 143 (34.5%) and 124 (30.0%) patients, respectively. AI-TCFA within the target lesion was significantly associated with the primary outcome [hazard ratio (HR) 1.99, 95% confidence interval (CI) 1.02-3.90, P = .04], while the HR for CL-TCFA was non-significant (1.67, 95% CI: .84-3.30, P = .14). When evaluating the complete pullback, AI-TCFA showed an even stronger association with the primary outcome (HR 5.50, 95% CI: 1.94-15.62, P < .001; negative predictive value 97.6%, 95% CI: 94.0%-99.3%).

Conclusions: AI-based OCT image analysis allows standardized identification of patients at increased risk of adverse cardiovascular outcome, offering an alternative to manual image analysis. Furthermore, AI-assisted evaluation of complete imaged segments results in better prognostic discrimatory value than evaluation of the target lesion only.

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehaf595DOI Listing

Publication Analysis

Top Keywords

primary outcome
12
thin-cap fibroatheromas
8
pectus-ai study
8
myocardial infarction
8
patients ai-tcfa
8
target lesion
8
image analysis
8
outcome
5
artificial intelligence-based
4
identification
4

Similar Publications

Background: There is conflicting literature regarding mortality outcomes associated with REBOA usage in patients with severe thoracic or abdominal trauma. Our study aims to assess the benefits and negative implications of REBOA use in adult trauma patients in hemorrhagic shock with severe thoracic or abdominal injuries.

Methods: This retrospective cohort analysis utilized the American College of Surgeons Trauma Quality Improvement Program Participant Use File (ACS-TQIP-PUF) database from 2017 to 2023 to evaluate adult patients with severe isolated thoracic or abdominal trauma undergoing REBOA placement.

View Article and Find Full Text PDF

Background: Sarcomas are rare cancer with a heterogeneous group of tumors. They affect both genders across all age groups and present significant heterogeneity, with more than 70 histological subtypes. Despite tailored treatments, the high metastatic potential of sarcomas remains a major factor in poor patient survival, as metastasis is often the leading cause of death.

View Article and Find Full Text PDF

Background: Out-of-hospital cardiac arrests (OHCAs) are a leading cause of death worldwide, yet first responder apps can significantly improve outcomes by mobilizing citizens to perform cardiopulmonary resuscitation before professional help arrives. Despite their importance, limited research has examined the psychological and behavioral factors that influence individuals' willingness to adopt these apps.

Objective: Given that first responder app use involves elements of both technology adoption and preventive health behavior, it is essential to examine this behavior from multiple theoretical perspectives.

View Article and Find Full Text PDF

Purpose: To report outcomes of suprachoroidal hemorrhage (SCH).

Methods: Retrospective non-randomized study of eyes with SCH from two sites (1/1/2013-12/31/2022). The primary outcome was the 6-month change in visual acuity (VA).

View Article and Find Full Text PDF

Long-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.

Neurology

October 2025

Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies - EpiCARE, Rome, Italy.

Objectives: Neuronal ceroid lipofuscinosis type 3 (CLN3) is a rare lysosomal storage disorder characterized by progressive neurodegeneration. No disease-modifying treatments are currently available. Miglustat, a substrate reduction therapy, has shown preclinical efficacy in CLN3 models (conference abstract).

View Article and Find Full Text PDF